Suppression of estrogenic activity by medroxyprogesterone acetate in tamoxifen-treated patients after surgery for breast cancer to reduce the risk of endometrial cancer development

Hiroyoshi Doihara, Shigemitsu Takashima, Akira Kurita, Shosuke Moriwaki

Research output: Contribution to journalArticle

Abstract

Background: Postoperative adjuvant tamoxifen (TAM) therapy in breast cancer patients may lead, albeit rarely, to endometrial cancer. Preventive measures are urgently needed. Methods: The study subjects were postmenopausal women who had undergone surgery for breast cancer. The control group (n=10) received no further therapy. Patients who had completed adjuvant TAM therapy were assigned to a medroxy-progesterone acetate (MPA; 400 mg/day orally for 4 weeks) group (n=15) or no MPA treatment group (no MPA group) (n=15). Uterine cervix cytodiagnosis was performed after completing the TAM therapy (initial), and 4 (4-week) and 16 (16-week) weeks later. The serum 17β-estradiol (E2) and progesterone concentrations were measured initially and at 4 weeks. The karyopyknotic index (KPI), eosinophilic index (EI) and maturation index (MI) were calculated from Papanicolaou-stained specimens. Results: The background parameters showed no biases. There were no differences in the KPI or EI between the no MPA and MPA groups. However, regarding the MI, after 4 weeks in the MPA group, the intermediate cells were significantly increased, while the superficial cells tended to be significantly decreased. Regarding the percent change from the initial value, after 4 weeks in the MPA group, the KPI and superficial cells were significantly decreased, and the intermediate cells were significantly increased. The estrogen activity level and the progesterone concentration were significantly lower in the MPA group compared with the no MPA group. Conclusions. The MPA administration clearly lowered the estrogenic activity, indicating that MPA therapy should be effective in reducing the risk of TAM-associated endometrial cancer.

Original languageEnglish
Pages (from-to)25-31
Number of pages7
JournalBreast Cancer
Volume3
Issue number1
DOIs
Publication statusPublished - Mar 1996

Fingerprint

Medroxyprogesterone Acetate
Tamoxifen
Endometrial Neoplasms
Breast Neoplasms
Progesterone
Therapeutics
Cytodiagnosis
Cervix Uteri
Estradiol
Estrogens
Acetates
Control Groups
Serum

Keywords

  • Breast cancer
  • Endometrial cancer
  • Medroxyprogesterone acetate
  • Tamoxifen

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)
  • Oncology

Cite this

Suppression of estrogenic activity by medroxyprogesterone acetate in tamoxifen-treated patients after surgery for breast cancer to reduce the risk of endometrial cancer development. / Doihara, Hiroyoshi; Takashima, Shigemitsu; Kurita, Akira; Moriwaki, Shosuke.

In: Breast Cancer, Vol. 3, No. 1, 03.1996, p. 25-31.

Research output: Contribution to journalArticle

@article{877780a73bec4323b6d02c8569e2146b,
title = "Suppression of estrogenic activity by medroxyprogesterone acetate in tamoxifen-treated patients after surgery for breast cancer to reduce the risk of endometrial cancer development",
abstract = "Background: Postoperative adjuvant tamoxifen (TAM) therapy in breast cancer patients may lead, albeit rarely, to endometrial cancer. Preventive measures are urgently needed. Methods: The study subjects were postmenopausal women who had undergone surgery for breast cancer. The control group (n=10) received no further therapy. Patients who had completed adjuvant TAM therapy were assigned to a medroxy-progesterone acetate (MPA; 400 mg/day orally for 4 weeks) group (n=15) or no MPA treatment group (no MPA group) (n=15). Uterine cervix cytodiagnosis was performed after completing the TAM therapy (initial), and 4 (4-week) and 16 (16-week) weeks later. The serum 17β-estradiol (E2) and progesterone concentrations were measured initially and at 4 weeks. The karyopyknotic index (KPI), eosinophilic index (EI) and maturation index (MI) were calculated from Papanicolaou-stained specimens. Results: The background parameters showed no biases. There were no differences in the KPI or EI between the no MPA and MPA groups. However, regarding the MI, after 4 weeks in the MPA group, the intermediate cells were significantly increased, while the superficial cells tended to be significantly decreased. Regarding the percent change from the initial value, after 4 weeks in the MPA group, the KPI and superficial cells were significantly decreased, and the intermediate cells were significantly increased. The estrogen activity level and the progesterone concentration were significantly lower in the MPA group compared with the no MPA group. Conclusions. The MPA administration clearly lowered the estrogenic activity, indicating that MPA therapy should be effective in reducing the risk of TAM-associated endometrial cancer.",
keywords = "Breast cancer, Endometrial cancer, Medroxyprogesterone acetate, Tamoxifen",
author = "Hiroyoshi Doihara and Shigemitsu Takashima and Akira Kurita and Shosuke Moriwaki",
year = "1996",
month = "3",
doi = "10.1007/BF02966959",
language = "English",
volume = "3",
pages = "25--31",
journal = "Breast Cancer",
issn = "1340-6868",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Suppression of estrogenic activity by medroxyprogesterone acetate in tamoxifen-treated patients after surgery for breast cancer to reduce the risk of endometrial cancer development

AU - Doihara, Hiroyoshi

AU - Takashima, Shigemitsu

AU - Kurita, Akira

AU - Moriwaki, Shosuke

PY - 1996/3

Y1 - 1996/3

N2 - Background: Postoperative adjuvant tamoxifen (TAM) therapy in breast cancer patients may lead, albeit rarely, to endometrial cancer. Preventive measures are urgently needed. Methods: The study subjects were postmenopausal women who had undergone surgery for breast cancer. The control group (n=10) received no further therapy. Patients who had completed adjuvant TAM therapy were assigned to a medroxy-progesterone acetate (MPA; 400 mg/day orally for 4 weeks) group (n=15) or no MPA treatment group (no MPA group) (n=15). Uterine cervix cytodiagnosis was performed after completing the TAM therapy (initial), and 4 (4-week) and 16 (16-week) weeks later. The serum 17β-estradiol (E2) and progesterone concentrations were measured initially and at 4 weeks. The karyopyknotic index (KPI), eosinophilic index (EI) and maturation index (MI) were calculated from Papanicolaou-stained specimens. Results: The background parameters showed no biases. There were no differences in the KPI or EI between the no MPA and MPA groups. However, regarding the MI, after 4 weeks in the MPA group, the intermediate cells were significantly increased, while the superficial cells tended to be significantly decreased. Regarding the percent change from the initial value, after 4 weeks in the MPA group, the KPI and superficial cells were significantly decreased, and the intermediate cells were significantly increased. The estrogen activity level and the progesterone concentration were significantly lower in the MPA group compared with the no MPA group. Conclusions. The MPA administration clearly lowered the estrogenic activity, indicating that MPA therapy should be effective in reducing the risk of TAM-associated endometrial cancer.

AB - Background: Postoperative adjuvant tamoxifen (TAM) therapy in breast cancer patients may lead, albeit rarely, to endometrial cancer. Preventive measures are urgently needed. Methods: The study subjects were postmenopausal women who had undergone surgery for breast cancer. The control group (n=10) received no further therapy. Patients who had completed adjuvant TAM therapy were assigned to a medroxy-progesterone acetate (MPA; 400 mg/day orally for 4 weeks) group (n=15) or no MPA treatment group (no MPA group) (n=15). Uterine cervix cytodiagnosis was performed after completing the TAM therapy (initial), and 4 (4-week) and 16 (16-week) weeks later. The serum 17β-estradiol (E2) and progesterone concentrations were measured initially and at 4 weeks. The karyopyknotic index (KPI), eosinophilic index (EI) and maturation index (MI) were calculated from Papanicolaou-stained specimens. Results: The background parameters showed no biases. There were no differences in the KPI or EI between the no MPA and MPA groups. However, regarding the MI, after 4 weeks in the MPA group, the intermediate cells were significantly increased, while the superficial cells tended to be significantly decreased. Regarding the percent change from the initial value, after 4 weeks in the MPA group, the KPI and superficial cells were significantly decreased, and the intermediate cells were significantly increased. The estrogen activity level and the progesterone concentration were significantly lower in the MPA group compared with the no MPA group. Conclusions. The MPA administration clearly lowered the estrogenic activity, indicating that MPA therapy should be effective in reducing the risk of TAM-associated endometrial cancer.

KW - Breast cancer

KW - Endometrial cancer

KW - Medroxyprogesterone acetate

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=77951508978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951508978&partnerID=8YFLogxK

U2 - 10.1007/BF02966959

DO - 10.1007/BF02966959

M3 - Article

AN - SCOPUS:77951508978

VL - 3

SP - 25

EP - 31

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 1

ER -